VLA

VIRALYTICS LIMITED - Announcements

0.00%

$1.75

Currently unlisted.

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile

See benefits

Announcements

Filter Results

All Price Sensitive Only

VLA	Removal from Official List at close 21/06/2018		21/06/18	223.86KB	Share
VLA	Implementation of Scheme of Arrangement		20/06/18	89.64KB	Share
VLA	Suspension from Official Quotation at close 05/06/18	PRICE SENSITIVE	05/06/18	227.31KB	Share
VLA	Lodgement of court orders with ASIC		05/06/18	536.97KB	Share
VLA	Correction to Scheme of Arrangement Timetable		04/06/18	89.03KB	Share
VLA	Federal Court of Australia approves scheme of arrangement	PRICE SENSITIVE	04/06/18	92.36KB	Share
VLA	VLA Shareholders Vote in Favour of Scheme of Arrangement	PRICE SENSITIVE	28/05/18	98.56KB	Share
VLA	Shareholder Meeting Scheme of Arrangement Presentation		28/05/18	626.92KB	Share
VLA	Shareholder Meeting Scheme of Arrangement Chairman's Address		28/05/18	95.26KB	Share
VLA	Update on Scheme of Arrangement	PRICE SENSITIVE	23/05/18	55.8KB	Share
VLA	Appendix 4C - quarterly	PRICE SENSITIVE	24/04/18	55.03KB	Share
VLA	Court approves convening of scheme meeting	PRICE SENSITIVE	20/04/18	2.35MB	Share
VLA	New CAVATAK Data at International Oncolytic Virus Conference	PRICE SENSITIVE	11/04/18	77.49KB	Share
VLA	Ceasing to be a substantial holder from MUFG		09/03/18	62.45KB	Share
VLA	Ceasing to be a substantial holder from MS		08/03/18	224.23KB	Share
VLA	Ceasing to be a substantial holder		06/03/18	118.51KB	Share
VLA	Becoming a substantial holder from MUFG		05/03/18	381.53KB	Share
VLA	Becoming a substantial holder from MS		02/03/18	345.52KB	Share
VLA	Ceasing to be a substantial holder		02/03/18	129.57KB	Share
VLA	Appendix 4D Half Yearly Report and Accounts	PRICE SENSITIVE	26/02/18	830.36KB	Share
VLA	MSD and Viralytics Announce Acquisition Agreement	PRICE SENSITIVE	21/02/18	2.76MB	Share
VLA	Appendix 4C - quarterly	PRICE SENSITIVE	24/01/18	180.42KB	Share
VLA	Ceasing to be a substantial holder		15/01/18	106.92KB	Share
VLA	Change of Director's Interest Notice		12/01/18	111.62KB	Share
VLA	Ceasing to be a substantial holder		12/01/18	108.01KB	Share
VLA	Appendix 3B		10/01/18	140.77KB	Share
VLA	Notice of Initial Subsubstantial Shareholder		09/01/18	173.14KB	Share
VLA	JP Morgan Healthcare conference, new investor presentation		08/01/18	70.46KB	Share
VLA	Viralytics Receives $6.4 Million R&D Tax Incentive	PRICE SENSITIVE	08/01/18	73.66KB	Share
VLA	Cleansing Notice		05/01/18	33.85KB	Share
VLA	Appendix 3B		05/01/18	148.32KB	Share
VLA	$29.6m Equity Placement to Lepu Medical Group of China	PRICE SENSITIVE	05/01/18	66.66KB	Share
VLA	Trading Halt	PRICE SENSITIVE	04/01/18	274.54KB	Share
VLA	Change of Director's Interest Notice x 4		15/12/17	496.41KB	Share
VLA	Ceasing to be a substantial holder		14/12/17	929.54KB	Share
VLA	Appendix 3B - Issue of Options and Performance Rights		12/12/17	179.94KB	Share
VLA	Change of Director's Interest Notice		06/12/17	145.01KB	Share
VLA	Ceasing to be a substantial holder from MUFG		04/12/17	55.86KB	Share
VLA	Change in substantial holding		04/12/17	125.35KB	Share
VLA	Ceasing to be a substantial holder from MS		04/12/17	183.21KB	Share
VLA	Becoming a substantial holder from MUFG		01/12/17	362.34KB	Share
VLA	Becoming a substantial holder from MS		01/12/17	528.52KB	Share
VLA	Chairman's Letter to Shareholders		28/11/17	69.1KB	Share
VLA	Results of Meeting		22/11/17	101.48KB	Share
VLA	AGM Presentation		22/11/17	2.34MB	Share
VLA	Chairman's Address to Shareholders		22/11/17	45.95KB	Share
VLA	New Data at SITC Meeting. Further Studies Announced	PRICE SENSITIVE	13/11/17	132.88KB	Share
VLA	Change of Director's Interest Notice		01/11/17	111.64KB	Share
VLA	Cleansing Notice		31/10/17	74.13KB	Share
VLA	Appendix 3B		31/10/17	151.96KB	Share
VLA	Viralytics to Present at 2017 SITC Annual Meeting		31/10/17	87.32KB	Share
VLA	Appendix 4C - quarterly	PRICE SENSITIVE	25/10/17	135.3KB	Share
VLA	Notice of Annual General Meeting/Proxy Form		23/10/17	388.87KB	Share
VLA	Annual Report to shareholders		23/10/17	1.55MB	Share
VLA	Date of Annual General Meeting		20/09/17	113.25KB	Share
VLA	Appendix 3B		15/09/17	151.74KB	Share
VLA	Viralytics Annual Report and Full Year Financial Results		18/08/17	97.35KB	Share
VLA	Appendix 4G and Corporate Governance Statement		18/08/17	214.1KB	Share
VLA	Appendix 4E and Full Year Statutory Accounts	PRICE SENSITIVE	18/08/17	1.44MB	Share
VLA	Becoming a substantial holder		07/08/17	145.75KB	Share
VLA	Change in substantial holding		02/08/17	65.47KB	Share
VLA	Change in substantial holding		02/08/17	113.89KB	Share
VLA	Change in substantial holding		27/07/17	165.08KB	Share
VLA	Appendix 4C - quarterly	PRICE SENSITIVE	18/07/17	70.95KB	Share
VLA	Becoming a substantial holder		18/07/17	120.84KB	Share
VLA	Bio-Marker Data from CANON Bladder Cancer Study Presented		26/06/17	125.24KB	Share
VLA	Change in substantial holding		13/06/17	415.09KB	Share
VLA	Update on MITCI and KEYNOTE 200 trials at ASCO Ann Meeting	PRICE SENSITIVE	06/06/17	92.15KB	Share
VLA	Change in substantial holding		23/05/17	61.75KB	Share
VLA	Ceasing to be a substantial holder		22/05/17	187.22KB	Share
VLA	Change of Director's Interest Notice		05/05/17	70.49KB	Share
VLA	Appendix 3B		05/05/17	147.08KB	Share
VLA	Appendix 3B		18/04/17	184.58KB	Share
VLA	Appendix 4C - quarterly	PRICE SENSITIVE	11/04/17	69.53KB	Share
VLA	Progress Report on KEYNOTE 200 at AACR Podium	PRICE SENSITIVE	05/04/17	84.18KB	Share
VLA	Promising Results MITCI Melanoma Trial at AACR Podium	PRICE SENSITIVE	05/04/17	115.7KB	Share
VLA	Promising Results CAPRA Melanoma Trial expand to 50 patients	PRICE SENSITIVE	04/04/17	409.9KB	Share
VLA	Invitation to Conference Call - MITCI Trial Update		30/03/17	101.67KB	Share
VLA	Becoming a substantial holder		06/03/17	281.12KB	Share
VLA	Viralytics to Present New CAVATAK Clinical Data at AACR	PRICE SENSITIVE	02/03/17	85.13KB	Share
VLA	Appendix 4D Half Yearly Report and Accounts	PRICE SENSITIVE	22/02/17	491.84KB	Share
VLA	Viralytics Receives $4.3 Million R&D Tax Incentive	PRICE SENSITIVE	13/02/17	55.89KB	Share
VLA	Appendix 4C - quarterly	PRICE SENSITIVE	27/01/17	78.68KB	Share
VLA	Becoming a substantial holder		06/12/16	751.33KB	Share
VLA	Change of Director's Interest Notice		05/12/16	78.31KB	Share
VLA	Change of Director's Interest Notice		24/11/16	361.51KB	Share
VLA	Change of Director's Interest Notice x 3		23/11/16	189.31KB	Share
VLA	Appendix 3B		23/11/16	186.28KB	Share
VLA	Results of Meeting		23/11/16	97.06KB	Share
VLA	AGM Presentation		23/11/16	3.51MB	Share
VLA	Chairman's Address to Shareholders		23/11/16	36.8KB	Share
VLA	Viralytics Announces Formation of Clinical Advisory Board		22/11/16	42.78KB	Share
VLA	Change in substantial holding		18/11/16	423.14KB	Share
VLA	Change of Directors Interest Notice		16/11/16	147.98KB	Share
VLA	Promising Advanced Melanoma Results - KEYTRUDA Combination	PRICE SENSITIVE	14/11/16	106.19KB	Share
VLA	Appendix 4C - quarterly-VLA.AX	PRICE SENSITIVE	26/10/16	60.69KB	Share
VLA	Notice of Annual General Meeting/Proxy Form-VLA.AX		21/10/16	793.34KB	Share
VLA	CAVATAK YERVOY Promising Results in Advanced Melanoma - ESMO-VLA.AX	PRICE SENSITIVE	10/10/16	121.85KB	Share
VLA	VLA update on CAVATAK KEYTRUDA Combination trials - ESMO-VLA.AX	PRICE SENSITIVE	10/10/16	82.2KB	Share
VLA	VLA presents at Oncolytic Virus Therapeutics Conference-VLA.AX	PRICE SENSITIVE	04/10/16	123.48KB	Share

VLA Removal from Official List at close 21/06/2018
21/06/18		223.86KB	Share
VLA Implementation of Scheme of Arrangement
20/06/18		89.64KB	Share
VLA Suspension from Official Quotation at close 05/06/18
05/06/18	PRICE SENSITIVE	227.31KB	Share
VLA Lodgement of court orders with ASIC
05/06/18		536.97KB	Share
VLA Correction to Scheme of Arrangement Timetable
04/06/18		89.03KB	Share
VLA Federal Court of Australia approves scheme of arrangement
04/06/18	PRICE SENSITIVE	92.36KB	Share
VLA VLA Shareholders Vote in Favour of Scheme of Arrangement
28/05/18	PRICE SENSITIVE	98.56KB	Share
VLA Shareholder Meeting Scheme of Arrangement Presentation
28/05/18		626.92KB	Share
VLA Shareholder Meeting Scheme of Arrangement Chairman's Address
28/05/18		95.26KB	Share
VLA Update on Scheme of Arrangement
23/05/18	PRICE SENSITIVE	55.8KB	Share
VLA Appendix 4C - quarterly
24/04/18	PRICE SENSITIVE	55.03KB	Share
VLA Court approves convening of scheme meeting
20/04/18	PRICE SENSITIVE	2.35MB	Share
VLA New CAVATAK Data at International Oncolytic Virus Conference
11/04/18	PRICE SENSITIVE	77.49KB	Share
VLA Ceasing to be a substantial holder from MUFG
09/03/18		62.45KB	Share
VLA Ceasing to be a substantial holder from MS
08/03/18		224.23KB	Share
VLA Ceasing to be a substantial holder
06/03/18		118.51KB	Share
VLA Becoming a substantial holder from MUFG
05/03/18		381.53KB	Share
VLA Becoming a substantial holder from MS
02/03/18		345.52KB	Share
VLA Ceasing to be a substantial holder
02/03/18		129.57KB	Share
VLA Appendix 4D Half Yearly Report and Accounts
26/02/18	PRICE SENSITIVE	830.36KB	Share
VLA MSD and Viralytics Announce Acquisition Agreement
21/02/18	PRICE SENSITIVE	2.76MB	Share
VLA Appendix 4C - quarterly
24/01/18	PRICE SENSITIVE	180.42KB	Share
VLA Ceasing to be a substantial holder
15/01/18		106.92KB	Share
VLA Change of Director's Interest Notice
12/01/18		111.62KB	Share
VLA Ceasing to be a substantial holder
12/01/18		108.01KB	Share
VLA Appendix 3B
10/01/18		140.77KB	Share
VLA Notice of Initial Subsubstantial Shareholder
09/01/18		173.14KB	Share
VLA JP Morgan Healthcare conference, new investor presentation
08/01/18		70.46KB	Share
VLA Viralytics Receives $6.4 Million R&D Tax Incentive
08/01/18	PRICE SENSITIVE	73.66KB	Share
VLA Cleansing Notice
05/01/18		33.85KB	Share
VLA Appendix 3B
05/01/18		148.32KB	Share
VLA $29.6m Equity Placement to Lepu Medical Group of China
05/01/18	PRICE SENSITIVE	66.66KB	Share
VLA Trading Halt
04/01/18	PRICE SENSITIVE	274.54KB	Share
VLA Change of Director's Interest Notice x 4
15/12/17		496.41KB	Share
VLA Ceasing to be a substantial holder
14/12/17		929.54KB	Share
VLA Appendix 3B - Issue of Options and Performance Rights
12/12/17		179.94KB	Share
VLA Change of Director's Interest Notice
06/12/17		145.01KB	Share
VLA Ceasing to be a substantial holder from MUFG
04/12/17		55.86KB	Share
VLA Change in substantial holding
04/12/17		125.35KB	Share
VLA Ceasing to be a substantial holder from MS
04/12/17		183.21KB	Share
VLA Becoming a substantial holder from MUFG
01/12/17		362.34KB	Share
VLA Becoming a substantial holder from MS
01/12/17		528.52KB	Share
VLA Chairman's Letter to Shareholders
28/11/17		69.1KB	Share
VLA Results of Meeting
22/11/17		101.48KB	Share
VLA AGM Presentation
22/11/17		2.34MB	Share
VLA Chairman's Address to Shareholders
22/11/17		45.95KB	Share
VLA New Data at SITC Meeting. Further Studies Announced
13/11/17	PRICE SENSITIVE	132.88KB	Share
VLA Change of Director's Interest Notice
01/11/17		111.64KB	Share
VLA Cleansing Notice
31/10/17		74.13KB	Share
VLA Appendix 3B
31/10/17		151.96KB	Share
VLA Viralytics to Present at 2017 SITC Annual Meeting
31/10/17		87.32KB	Share
VLA Appendix 4C - quarterly
25/10/17	PRICE SENSITIVE	135.3KB	Share
VLA Notice of Annual General Meeting/Proxy Form
23/10/17		388.87KB	Share
VLA Annual Report to shareholders
23/10/17		1.55MB	Share
VLA Date of Annual General Meeting
20/09/17		113.25KB	Share
VLA Appendix 3B
15/09/17		151.74KB	Share
VLA Viralytics Annual Report and Full Year Financial Results
18/08/17		97.35KB	Share
VLA Appendix 4G and Corporate Governance Statement
18/08/17		214.1KB	Share
VLA Appendix 4E and Full Year Statutory Accounts
18/08/17	PRICE SENSITIVE	1.44MB	Share
VLA Becoming a substantial holder
07/08/17		145.75KB	Share
VLA Change in substantial holding
02/08/17		65.47KB	Share
VLA Change in substantial holding
02/08/17		113.89KB	Share
VLA Change in substantial holding
27/07/17		165.08KB	Share
VLA Appendix 4C - quarterly
18/07/17	PRICE SENSITIVE	70.95KB	Share
VLA Becoming a substantial holder
18/07/17		120.84KB	Share
VLA Bio-Marker Data from CANON Bladder Cancer Study Presented
26/06/17		125.24KB	Share
VLA Change in substantial holding
13/06/17		415.09KB	Share
VLA Update on MITCI and KEYNOTE 200 trials at ASCO Ann Meeting
06/06/17	PRICE SENSITIVE	92.15KB	Share
VLA Change in substantial holding
23/05/17		61.75KB	Share
VLA Ceasing to be a substantial holder
22/05/17		187.22KB	Share
VLA Change of Director's Interest Notice
05/05/17		70.49KB	Share
VLA Appendix 3B
05/05/17		147.08KB	Share
VLA Appendix 3B
18/04/17		184.58KB	Share
VLA Appendix 4C - quarterly
11/04/17	PRICE SENSITIVE	69.53KB	Share
VLA Progress Report on KEYNOTE 200 at AACR Podium
05/04/17	PRICE SENSITIVE	84.18KB	Share
VLA Promising Results MITCI Melanoma Trial at AACR Podium
05/04/17	PRICE SENSITIVE	115.7KB	Share
VLA Promising Results CAPRA Melanoma Trial expand to 50 patients
04/04/17	PRICE SENSITIVE	409.9KB	Share
VLA Invitation to Conference Call - MITCI Trial Update
30/03/17		101.67KB	Share
VLA Becoming a substantial holder
06/03/17		281.12KB	Share
VLA Viralytics to Present New CAVATAK Clinical Data at AACR
02/03/17	PRICE SENSITIVE	85.13KB	Share
VLA Appendix 4D Half Yearly Report and Accounts
22/02/17	PRICE SENSITIVE	491.84KB	Share
VLA Viralytics Receives $4.3 Million R&D Tax Incentive
13/02/17	PRICE SENSITIVE	55.89KB	Share
VLA Appendix 4C - quarterly
27/01/17	PRICE SENSITIVE	78.68KB	Share
VLA Becoming a substantial holder
06/12/16		751.33KB	Share
VLA Change of Director's Interest Notice
05/12/16		78.31KB	Share
VLA Change of Director's Interest Notice
24/11/16		361.51KB	Share
VLA Change of Director's Interest Notice x 3
23/11/16		189.31KB	Share
VLA Appendix 3B
23/11/16		186.28KB	Share
VLA Results of Meeting
23/11/16		97.06KB	Share
VLA AGM Presentation
23/11/16		3.51MB	Share
VLA Chairman's Address to Shareholders
23/11/16		36.8KB	Share
VLA Viralytics Announces Formation of Clinical Advisory Board
22/11/16		42.78KB	Share
VLA Change in substantial holding
18/11/16		423.14KB	Share
VLA Change of Directors Interest Notice
16/11/16		147.98KB	Share
VLA Promising Advanced Melanoma Results - KEYTRUDA Combination
14/11/16	PRICE SENSITIVE	106.19KB	Share
VLA Appendix 4C - quarterly-VLA.AX
26/10/16	PRICE SENSITIVE	60.69KB	Share
VLA Notice of Annual General Meeting/Proxy Form-VLA.AX
21/10/16		793.34KB	Share
VLA CAVATAK YERVOY Promising Results in Advanced Melanoma - ESMO-VLA.AX
10/10/16	PRICE SENSITIVE	121.85KB	Share
VLA VLA update on CAVATAK KEYTRUDA Combination trials - ESMO-VLA.AX
10/10/16	PRICE SENSITIVE	82.2KB	Share
VLA VLA presents at Oncolytic Virus Therapeutics Conference-VLA.AX
04/10/16	PRICE SENSITIVE	123.48KB	Share

REFRESH

1 2 3 4 5 6

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

VIRALYTICS LIMITED - Announcements

Corporate SpotlightNot Yet Available

Announcements

Top Stories

Corporate Spotlight
Not Yet Available